Market Cap : 126.55 B | Enterprise Value : 139.65 B | PE Ratio : 25.52 | PB Ratio : 2.40 |
---|
NYSE:MDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medtronic's cash to debt ratio for the quarter that ended in Apr. 2022 was 0.44.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Medtronic couldn't pay off its debt using the cash in hand for the quarter that ended in Apr. 2022.
The historical rank and industry rank for Medtronic's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Medtronic's highest Cash to Debt Ratio was 7.76. The lowest was 0.21. And the median was 0.86.
The historical data trend for Medtronic's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Medtronic's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Medtronic's Cash to Debt Ratio for the fiscal year that ended in Apr. 2022 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 10573 | / | (3742 | + | 20372) | |
= | 0.44 |
Medtronic's Cash to Debt Ratio for the quarter that ended in Apr. 2022 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 10573 | / | (3742 | + | 20372) | |
= | 0.44 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Medtronic's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Fong Ivan K | officer: EVP GENERAL COUNSEL & SECR | 3M CENTER ST. PAUL MN 55144-1000 |
Kirk Jennifer M | officer: Chief Accounting Officer | 5 GREENWAY PLAZA SUITE 110 HOUSTON TX 77046 |
Lofton Kevin E | director | GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Wall Brett A. | officer: EVP & Group Pres Restora Thera | 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Salmon Sean | officer: EVP & Group President Diabetes | MEDTRONIC PLC, 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Goldsmith Andrea Jo | director | 1220 AUGUSTA DRIVE SUITE 600 HOUSTON TX 77057 |
Liddicoat John R | officer: EVP & President of Americas | MEDTRONIC PLC 710 MEDTRONIC PKWY, MS LC300 MINNEAPOLIS MN 55432 |
White Robert John | officer: EVP & President MITG | MEDTRONIC PLC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Parkhill Karen L | officer: EVP & Chief Financial Officer | 1717 MAIN STREET, MC 6402 DALLAS TX 75201 |
Reddy Preetha | director | APOLLO HOSPITALS 21 GREAMS LN, OFF GREAMS RD CHENNAI K7 600006 |
Ellis Gary Lee | officer: EVP & Chief Financial Officer | THE TORO COMPANY 8111 LYNDALE AVENUE SOUTH BLOOMINGTON MN 55420 |
Hanson Bryan C | officer: EVP AND PRESIDENT, COVIDIEN | ZIMMER BIOMET HOLDINGS 345 E. MAIN STREET WARSAW IN 46580 |
Hakami Hooman | officer: EVP & Group President Diabetes | 710 MEDTRONIC PKWY MSLC300 MINNEAPOLIS MN 55432 |
Oconnell Christopher J | officer: See Remarks | MEDTRONIC, INC. 710 MEDTRONIC PKWY MINNEAPOLIS MN 55432 |
Lenehan James T | director | C/O MEDTRONIC INC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Other Sources
By Zacks 2022-03-03
By Zacks 2022-04-01
By Zacks 2022-03-24
By Zacks 2022-04-05
By tipranks.com 2022-03-21
By Fool 2022-03-02
By Zacks 2022-03-15
By Zacks 2022-03-01
By Zacks 2022-03-28
By Zacks 2022-02-22
By Zacks 2022-03-07
By Zacks 2022-02-22
By Zacks 2022-04-05